ERBB2 and non-small cell lung carcinoma: Additionally, a systematic literature review was conducted to offer a comprehensive overview of the existing evidence concerning the prevalence of HER2 mutation/amplification in NSCLC, as well as the efficacy of HER2-targeted therapies observed in prospective clinical trials involving NSCLC patients with HER2 alterations.